Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulla Vanleeuw

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
BMC Cancer|March 28, 2008
Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasisJulie Decock, Wouter Hendrickx, Ulla Vanleeuw, et al.
Translational Oncology|July 19, 2024
Potentially actionable targets in synovial sarcoma: A tissue microarray studyLore De Cock, Flavia Paternostro, Ulla Vanleeuw, et al.
Translational Oncology|May 1, 2015
Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft ModelsThomas Van Looy, Agnieszka Wozniak, Giuseppe Floris, et al.
Molecular Cancer Therapeutics|August 10, 2011
The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumorsGiuseppe Floris, Maria Debiec-Rychter, Agnieszka Wozniak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2023
Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line-Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)Luna De Sutter, Agnieszka Wozniak, Jasper Verreet, et al.
Translational Oncology|December 16, 2014
Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft ModelsHaifu Li, Agnieszka Wozniak, Raf Sciot, et al.
Clinical Sarcoma Research|August 19, 2014
Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitorsThomas Van Looy, Yemarshet Kelemework Gebreyohannes, Agnieszka Wozniak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacyThomas Van Looy, Agnieszka Wozniak, Giuseppe Floris, et al.
International Journal of Cancer|April 9, 2026
Urokinase Plasminogen Activator Receptor-Associated Protein (uPARAP) as a Potential Next Generation Molecular Target for Treatment of Gastrointestinal Stromal Tumors (GIST)Chao-Chi Wang, Flavia Paternostro, Agnieszka Wozniak, et al.
Molecular Cancer Therapeutics|June 2, 2017
<i>In Vivo</i> Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft ModelsJasmien Cornillie, Agnieszka Wozniak, Peter Pokreisz, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
BMC Cancer|March 28, 2008
Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasisJulie Decock, Wouter Hendrickx, Ulla Vanleeuw, et al.
Translational Oncology|July 19, 2024
Potentially actionable targets in synovial sarcoma: A tissue microarray studyLore De Cock, Flavia Paternostro, Ulla Vanleeuw, et al.
Translational Oncology|May 1, 2015
Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft ModelsThomas Van Looy, Agnieszka Wozniak, Giuseppe Floris, et al.
Molecular Cancer Therapeutics|August 10, 2011
The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumorsGiuseppe Floris, Maria Debiec-Rychter, Agnieszka Wozniak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2023
Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line-Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)Luna De Sutter, Agnieszka Wozniak, Jasper Verreet, et al.
Translational Oncology|December 16, 2014
Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft ModelsHaifu Li, Agnieszka Wozniak, Raf Sciot, et al.
Clinical Sarcoma Research|August 19, 2014
Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitorsThomas Van Looy, Yemarshet Kelemework Gebreyohannes, Agnieszka Wozniak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacyThomas Van Looy, Agnieszka Wozniak, Giuseppe Floris, et al.
International Journal of Cancer|April 9, 2026
Urokinase Plasminogen Activator Receptor-Associated Protein (uPARAP) as a Potential Next Generation Molecular Target for Treatment of Gastrointestinal Stromal Tumors (GIST)Chao-Chi Wang, Flavia Paternostro, Agnieszka Wozniak, et al.
Molecular Cancer Therapeutics|June 2, 2017
<i>In Vivo</i> Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft ModelsJasmien Cornillie, Agnieszka Wozniak, Peter Pokreisz, et al.
Pageof 2